AI-enabled ECG models move prognosis closer to the bedside
Artificial intelligence is changing what a standard electrocardiogram can do. In this systematic review and narrative synthesis, AI-enhanced electrocardiography was evaluated as a prognostic tool for all-cause mortality, cardiovascular mortality, and major adverse cardiovascular events in adults, with the search spanning PubMed, Cochrane CENTRAL, IEEE Xplore, and Google Scholar through November 2025. Thirteen studies met eligibility criteria, together covering roughly 5.9 million patients.
The scale matters because conventional risk scores often leave a wide band of uncertainty in real-world cardiovascular care. ECGs are already ubiquitous, inexpensive, and repeatable, yet they are usually treated as diagnostic snapshots rather than dynamic prognostic instruments. Deep learning changes that equation by extracting high-dimensional patterns from raw waveforms that human interpretation does not routinely capture. In practical terms, the machine is not reading the ECG the way a cardiologist does; it is mining signal fragments, intervals, morphology, and subtle beat-to-beat relationships that may reflect occult myocardial disease, autonomic imbalance, conduction abnormalities, or systemic illness burden.
Mortality prediction showed the most consistent signal
Eleven of the 13 studies examined all-cause mortality, and eight of those focused on short-term horizons ranging from 30 days to 1 year. Four studies evaluated cardiovascular mortality. Eight studies assessed MACE, split evenly between composite event definitions and individual components.
Across the mortality studies, model performance was strong enough to warrant attention, with reported c-statistics ranging from 0.70 to 0.89. Those values place the better-performing models well beyond chance discrimination and into a range that could complement existing clinical risk assessment. The review did not present one uniform model or one uniform population, and that variability prevents a simple pooled declaration of superiority. Still, the repeated appearance of usable prognostic performance across separate cohorts suggests that ECG-derived risk signatures are not random artifacts of one dataset.
A single 12-lead tracing can therefore function as a compact biomarker of biological aging, subclinical structural heart disease, and overall physiologic reserve.
CNNs dominated the technical approach
Most included studies relied on convolutional neural networks trained on raw ECG waveforms. That choice is clinically important. CNNs are especially suited to pattern recognition in ordered signal data, and ECG tracings are dense with repeating temporal structures that can carry prognostic information beyond conventional interval measurements. The models were not simply learning whether a tracing looked “abnormal” in the usual sense; they were learning representations that linked waveform features to future outcomes.
This approach also helps explain why the ECG remains attractive in risk prediction. It is already present in outpatient clinics, emergency departments, wards, and preoperative settings. If a validated AI layer can transform an existing test into a prognostic screen, the incremental cost of implementation may be modest compared with the clinical value of earlier recognition of risk. The promise is strongest in settings where decisions are made quickly and where laboratory or imaging data are incomplete.
Event definitions varied enough to limit direct comparison
Heterogeneity ran through the evidence base. Definitions of mortality and MACE were not standardized, and follow-up duration varied across studies. Some cohorts concentrated on near-term outcomes, while others used longer observation windows. Even the label MACE did not always mean the same thing from one study to the next, with some focusing on composite endpoints and others examining individual cardiovascular components.
This is the central barrier to immediate clinical deployment. A model that performs well for one endpoint definition cannot automatically be assumed to perform the same way when the endpoint changes, especially when predictors are extracted from a signal as compact and context-dependent as the ECG. Event ascertainment, population mix, and baseline risk all shape the apparent accuracy of a prognostic algorithm. Without standardization, two studies may seem to test the same question while actually measuring different clinical realities.
Why the ECG may carry prognostic information beyond rhythm and ischemia
The biological logic behind AI-ECG prognosis is plausible. Cardiovascular mortality and MACE are not driven solely by overt ischemia or arrhythmia. They also reflect cumulative myocardial injury, ventricular remodeling, conduction disease, autonomic tone, metabolic stress, and systemic inflammation. Those processes can leave faint but persistent signatures in the waveform long before they trigger a recognizable clinical event.
Deep learning may be identifying these patterns because it is not restricted to textbook criteria. A human reader may notice Q waves, ST-T changes, or conduction delay. The algorithm may also detect subtler alterations in repolarization heterogeneity, interval variation, or morphology patterns that correlate with adverse outcomes. In that sense, the ECG becomes a compressed portrait of disease burden rather than a narrow binary test.
Prospective validation still separates signal from practice
Even with strong discrimination in some cohorts, the review stops short of supporting routine implementation. Prospective validation remains necessary, along with external testing across health systems, age groups, and clinical settings. Standardized endpoint definitions will be essential if future studies are to be meaningfully compared or combined. Without those safeguards, performance estimates may remain impressive on paper while proving difficult to translate into real-world triage, outpatient surveillance, or inpatient decision support.
There is also a bedside question hidden inside the algorithmic one: what action should follow a high-risk AI-ECG result? A prognostic signal only matters if it changes care. That could mean closer follow-up, more aggressive management of cardiovascular risk factors, earlier imaging, or more careful review for occult heart disease. None of those pathways is automatic, and none should be assumed without evidence that acting on the model improves outcomes.
For now, the evidence supports cautious optimism rather than immediate replacement of established tools. AI-enabled ECG models have shown consistent prognostic potential across large adult cohorts, but the field still needs harmonized endpoints, prospective testing, and implementation studies that answer the practical question: when the algorithm flags risk, what should the clinician do next?